ABY-035

BIOLOGICAL3 trials

Sponsors

Affibody, ACELYRIN Inc., Inmagene LLC

Conditions

Ankylosing SpondylitisPlaque PsoriasisPsoriatic Arthritis

Phase 2

A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

CompletedNCT03591887

AffibodyPlaque Psoriasis

Start: 2018-03-07End: 2021-12-03Updated: 2023-06-08

A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis

CompletedNCT04713072

ACELYRIN Inc.Psoriatic Arthritis

Start: 2020-08-04End: 2022-01-27Updated: 2024-02-09

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

TerminatedNCT04795141

Inmagene LLCAnkylosing Spondylitis

Start: 2021-08-24End: 2022-08-30Updated: 2023-07-12

Related Papers

Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

mAbs2023-05-1553 citations